PTC Therapeutics, Inc. Paid-in-Kind Interest
PTC Therapeutics, Inc. (PTCT) reported Paid-in-Kind Interest of $22.60 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-21.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2023-02-21
- PTC Therapeutics, Inc. paid-in-kind interest for the quarter ending 2020-12-31 was $5.92M, a 8.74% increase year-over-year.
- PTC Therapeutics, Inc. paid-in-kind interest for the quarter ending 2020-09-30 was $5.68M, a 124.88% increase year-over-year.
- PTC Therapeutics, Inc. paid-in-kind interest for the quarter ending 2020-06-30 was $5.53M, a 166.96% increase year-over-year.
- PTC Therapeutics, Inc. paid-in-kind interest for the quarter ending 2020-03-31 was $5.46M, a 175.43% increase year-over-year.
- PTC Therapeutics, Inc. paid-in-kind interest for fiscal 2020 was $22.60M, a 87.89% increase from fiscal 2019.
- PTC Therapeutics, Inc. paid-in-kind interest for fiscal 2019 was $12.03M, a 59.98% increase from fiscal 2018.
- PTC Therapeutics, Inc. paid-in-kind interest for fiscal 2018 was $7.52M, a 11.30% increase from fiscal 2017.
- PTC Therapeutics, Inc. paid-in-kind interest for fiscal 2017 was $6.75M, a 11.38% increase from fiscal 2016.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 6 month as first filed | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 9 month as first filed | Paid-in-Kind Interest 12 month | Paid-in-Kind Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $11.61M derived: sum of 2 quarters · filed 2023-02-21 | $17.14M derived: sum of 3 quarters · filed 2023-02-21 | $22.60M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $5.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $11.22M derived: sum of 2 quarters · filed 2021-10-28 | $16.68M 10-Q · filed 2021-10-28 | $22.12M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2020-06-30 | $5.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $10.99M 10-Q · filed 2021-07-29 | $16.44M derived: sum of 3 quarters · filed 2022-02-22 | $18.96M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2020-03-31 | $5.46M 10-Q · filed 2021-05-04 | $10.90M derived: sum of 2 quarters · filed 2022-02-22 | $13.43M derived: sum of 3 quarters · filed 2022-02-22 | $15.50M derived: sum of 4 quarters · filed 2022-02-22 | |||
| 2019-12-31 | $5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $7.97M derived: sum of 2 quarters · filed 2022-02-22 | $10.04M derived: sum of 3 quarters · filed 2022-02-22 | $12.03M 10-K · filed 2022-02-22 | |||
| 2019-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $4.60M derived: sum of 2 quarters · filed 2020-10-29 | $6.58M 10-Q · filed 2020-10-29 | $8.54M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $4.05M 10-Q · filed 2020-08-05 | $6.01M derived: sum of 3 quarters · filed 2021-02-25 | $7.93M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $1.98M 10-Q · filed 2020-04-30 | $3.94M derived: sum of 2 quarters · filed 2021-02-25 | $5.86M derived: sum of 3 quarters · filed 2021-02-25 | $7.72M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.87M derived: sum of 2 quarters · filed 2021-02-25 | $5.74M derived: sum of 3 quarters · filed 2021-02-25 | $7.52M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $3.78M derived: sum of 2 quarters · filed 2019-10-30 | $5.56M 10-Q · filed 2019-10-30 | $7.32M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $3.64M 10-Q · filed 2019-08-06 | $5.40M derived: sum of 3 quarters · filed 2020-03-02 | $7.13M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | $1.78M 10-Q · filed 2019-05-02 | $3.54M derived: sum of 2 quarters · filed 2020-03-02 | $5.26M derived: sum of 3 quarters · filed 2020-03-02 | $6.93M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $3.48M derived: sum of 2 quarters · filed 2020-03-02 | $5.16M derived: sum of 3 quarters · filed 2020-03-02 | $6.75M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $3.40M derived: sum of 2 quarters · filed 2018-11-05 | $5.00M 10-Q · filed 2018-11-05 | $6.58M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $3.27M 10-Q · filed 2018-08-07 | $4.85M derived: sum of 3 quarters · filed 2019-03-01 | $6.40M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | $1.60M 10-Q · filed 2018-05-09 | $3.18M derived: sum of 2 quarters · filed 2019-03-01 | $4.72M derived: sum of 3 quarters · filed 2019-03-01 | $6.22M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $3.12M derived: sum of 2 quarters · filed 2019-03-01 | $4.62M derived: sum of 3 quarters · filed 2019-03-01 | $6.07M 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $3.04M derived: sum of 2 quarters · filed 2017-11-02 | $4.49M 10-Q · filed 2017-11-02 | $5.90M derived: sum of 4 quarters · filed 2018-03-06 | |||
| 2016-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $2.94M 10-Q · filed 2017-08-09 | $4.35M derived: sum of 3 quarters · filed 2018-03-06 | ||||
| 2016-03-31 | $1.45M 10-Q · filed 2017-05-08 | $2.86M derived: sum of 2 quarters · filed 2018-03-06 | |||||
| 2015-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $2.15M 10-K · filed 2018-03-06 | |||||
| 2015-09-30 | $736.00K 10-Q · filed 2016-11-03 | ||||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 | ||||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.00K derived: sum of 2 quarters · filed 2016-02-29 | $26.00K derived: sum of 3 quarters · filed 2016-02-29 | $6.05M 10-K · filed 2016-02-29 | $6.05M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $26.00K derived: sum of 2 quarters · filed 2014-11-06 | $6.05M 10-Q · filed 2014-11-06 | $6.05M 10-Q · filed 2013-11-14 | $6.07M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $6.04M 10-Q · filed 2014-08-07 | $6.04M 10-Q · filed 2013-08-13 | $6.07M derived: sum of 3 quarters · filed 2015-03-02 | $6.11M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $6.02M 10-Q · filed 2014-05-06 | $6.04M derived: sum of 2 quarters · filed 2015-03-02 | $6.09M derived: sum of 3 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $21.58K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $70.90K derived: sum of 2 quarters · filed 2015-03-02 | $226.00K 10-K · filed 2015-03-02 | $225.73K 10-K · filed 2014-03-06 | |||
| 2012-09-30 | $49.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $204.42K 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | $155.10K 10-Q · filed 2013-08-13 | ||||||
| 2011-12-31 | $416.61K 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |